ArticleProbiotics and antimicrobial proteins2026
A Fucose-containing Hetero-exopolysaccharide From Levilactobacillus brevis B151 Exhibits Potent Antimicrobial, Antibiofilm, and Antioxidant Activities.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Exopolysaccharides (EPSs) have recently emerged as significant substances due to their remarkable biological properties. This research aimed to analyze EPS B151 extracted from Levilactobacillus brevis B151 and evaluate its biological activities. EPS B151 was obtained at a yield of 438 mg/L. Structural analysis using the Congo red method and Fourier transform infrared spectroscopy (FTIR) revealed a random coil structure and characteristic typical carbohydrate peaks (O-H, C-H, C = O, and C-O-C), along with a pyranose ring containing both α- and β-glycosidic bonds. Scanning electron microscopy (SEM) revealed a porous, irregular, and loosely compact morphology. High-pressure liquid chromatography (HPLC) analysis indicated that EPS B151 is a heteropolysaccharide composed of mannose, ribose, glucosamine, glucuronic acid, glucose, galactose, and the rare sugar fucose. This unique composition is the first reported for an L. brevis-derived EPS. EPS B151 demonstrated significant antimicrobial activity against Staphylococcus aureus KFRI00188 and Listeria monocytogenes ATCC3596, inhibiting growth and cell viability in a dose-dependent manner, with bactericidal effects confirmed by propidium iodide staining and SEM analysis. It also inhibited biofilm formation (up to 58.09 ± 2.97% for Staph. aureus and 51.53 ± 3.84% for L. monocytogenes) in a dose-dependent manner. Furthermore, EPS B151 demonstrated potent antioxidant activity in multiple in vitro assays, including ABTS
Indexed as
Identifiers
41222844What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.